Novel peroxisome proliferator-activated receptor ligands for Type 2 diabetes and the metabolic syndrome

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.12, Iss.9, 2003-09, pp. : 1489-1500

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Gene-Nutrient Interaction in Type 2 Diabetes: An Appraisal of the Role of the Peroxisome Proliferator-Activated Receptor Pathway

Current Pharmacogenomics, Vol. 3, Iss. 2, 2005-06 ,pp. : 119-128

Bentham Science Publishers

Access to resources Recommend Favorite

Design, Synthesis and Evaluation of Peroxisome Proliferator-Activated Receptor /&bgr;Dual Agonists for the Treatment of Type 2 Diabetes

Letters in Drug Design & Discovery, Vol. 4, Iss. 1, 2007-01 ,pp. : 27-32

Bentham Science Publishers

Access to resources Recommend Favorite

Peroxisome proliferator-activated receptor ligands in atherosclerosis

By Viles-Gonzalez Juan F Choi Brian G Fuster Valentin Badimon Juan J

Expert Opinion on Investigational Drugs, Vol. 13, Iss. 11, 2004-11 ,pp. : 1393-1403

Informa Healthcare

Access to resources Recommend Favorite

Peroxisome Proliferator-Activated Receptor (PPAR)&bgr; /&dgr;: A New Potential Therapeutic Target for the Treatment of Metabolic Syndrome

Current Molecular Pharmacology, Vol. 2, Iss. 1, 2009-01 ,pp. : 46-55

Bentham Science Publishers

Access to resources Recommend Favorite

Recent Updates on Peroxisome Proliferator-Activated Receptor δ Agonists for the Treatment of Metabolic Syndrome

Medicinal Chemistry, Vol. 12, Iss. 1, 2016-02 ,pp. : 3-21

Bentham Science Publishers

Access to resources Recommend Favorite